Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 14;13(1):158.
doi: 10.3390/jpm13010158.

Direct Oral Anticoagulants for Stroke and Systemic Embolism Prevention in Patients with Left Ventricular Thrombus

Minerva Codruta Badescu  1   2 , Victorita Sorodoc  1   3 , Catalina Lionte  1   3 , Anca Ouatu  1   2 , Raluca Ecaterina Haliga  1   3 , Alexandru Dan Costache  1   4 , Oana Nicoleta Buliga-Finis  1   2 , Ioan Simon  5 , Laurentiu Sorodoc  1   3 , Irina-Iuliana Costache  1   6 , Ciprian Rezus  1   2
Affiliations
Review

Direct Oral Anticoagulants for Stroke and Systemic Embolism Prevention in Patients with Left Ventricular Thrombus

Minerva Codruta Badescu et al. J Pers Med. .

Abstract

In recent years, direct oral anticoagulants (DOAC) have accumulated evidence of efficacy and safety in various clinical scenarios and are approved for a wide spectrum of indications. Still, they are currently used off-label for left ventricular thrombus owing to a paucity of evidence. For the same reason, there is a lack of guideline indication as well. Our work is based on an exhaustive analysis of the available literature and provides a structured and detailed update on the use of DOACs in patients with left ventricle thrombus. The safety and efficacy of DOACs were analyzed in particular clinical scenarios. As far as we know, this is the first paper that analyzes DOACs in this approach.

Keywords: COVID-19; direct oral anticoagulants; hypertrophic cardiomyopathy; left ventricular thrombus; myocarditis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The main determinants of left intraventricular thrombosis and oral anticoagulant treatment options.
See this image and copyright information in PMC

References

    1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomstrom-Lundqvist C., Boriani G., Castella M., Dan G.A., Dilaveris P.E., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612. - DOI - PubMed
    1. Ghalyoun B.A., Lempel M., Shaaban H., Shamoon F. Successful resolution with apixaban of a massive left atrial appendage thrombus due to nonrheumatic atrial fibrillation: A case report and review. Ann. Card. Anaesth. 2018;21:76–77. - PMC - PubMed
    1. Vidal A., Vanerio G. Dabigatran and left atrial appendage thrombus. J. Thromb. Thrombolysis. 2012;34:545–547. doi: 10.1007/s11239-012-0747-1. - DOI - PubMed
    1. Gaznabi S., Abugroun A., Mahbub H., Campos E. Successful Resolution of a Large Left Atrial and Left Atrial Appendage Thrombus with Rivaroxaban. Case Rep. Cardiol. 2019;2019:6076923. doi: 10.1155/2019/6076923. - DOI - PMC - PubMed
    1. Lip G.Y., Hammerstingl C., Marin F., Cappato R., Meng I.L., Kirsch B., van Eickels M., Cohen A., X-TRA Study and CLOT-AF Registry Investigators Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF) Am. Heart J. 2016;178:126–134. doi: 10.1016/j.ahj.2016.05.007. - DOI - PubMed